Michigan hospitals are systematically exploiting a program for low-income patients, according to a new report.

As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the 340B Drug Pricing Program and the legal battle to stop it.

An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug ...

TN's U.S. Rep. Diana Harshbarger (R-01) has introduced the 340B Access Act to ensure savings benefit everyone, including ...

The 340B Drug Pricing Program was meant to help low-income patients, writes Rick Dowlearn, but it’s being used by hospitals ...

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

Congress must pass Rep. Diana Harshbarger's bipartisan proposal to ensure federal 340B dollars are used as intended.

Bristol-Myers Squibb has become the latest drugmaker in the US to file a legal challenge to a block on a drug rebate model opposed by a Health and Human Services (HHS) department. Specifically, BMS is ...